Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine Chen

Blood (2018) 132 (24): 2546–2554.

https://doi.org/10.1182/blood-2018-06-858852

Published: 2018

Includes: Supplemental data

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Philippe Moreau, MDPhD, Albert Oriol, MD, Jonathan L. Kaufman, MD, Heather Sutherland, MD, Marc Lalancette, MD FRCP, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, MD PhD, Miles Prince, MD FRACP, FRCPA, Tara Cochrane, Lisa O'Rourke, MSN, RN, Kaida Wu, Jordan M. Schecter, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1883.

https://doi.org/10.1182/blood.V130.Suppl_1.1883.1883

Published: 2017

Journal Articles

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Wasithep Limvorapitak, MD, Michael J Barnett, BM, Donna Hogge, Donna L Forrest, MD, Thomas J Nevill, MD, Sujaatha Narayanan, MBBS, Maryse Power, MB, Stephen H Nantel, MD, Raewyn Broady, MBChB, FRACP, Kevin W Song, MD, Cynthia L Toze, MD, Yasser Abou Mourad, MD, Heather Sutherland, MD, Alina S Gerrie, MD, Jennifer White, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 4544.

https://doi.org/10.1182/blood.V130.Suppl_1.4544.4544

Published: 2017

Journal Articles

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Suzanne Trudel, MD FRCP(C), Nikoletta Lendvai, MD PhD, Rakesh Popat, MD PhD, Peter M. Voorhees, MD, Brandi Reeves, MD, Edward N. Libby, III, MD, Paul G Richardson, MD, Larry Anderson, MD PhD, Heather Sutherland, MD, Kwee Yong, PhD, Axel Hoos, MD PhD, Michele Gorczyca, MS, Soumi Lahiri, PhD, Zangdong He, PhD, Roxanne C Jewell, PhD, Joanna B. Opalinska, MD PhD, Adam D. Cohen, MD

Blood (2017) 130 (Supplement 1): 741.

https://doi.org/10.1182/blood.V130.Suppl_1.741.741

Published: 2017

Journal Articles

Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)

Nizar J. Bahlis, MD, Heather Sutherland, MD, Darrell J White, MD, Michael Sebag, MD PhD, Suzanne Lentzsch, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD, Cristina J. Gasparetto, MD, Gary J Schiller, MD, Richard LeBlanc, MDFRCPC, William Bensinger, MD, Brea Lipe, MD, Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, BS, Jatin Shah, MD, Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3135.

https://doi.org/10.1182/blood.V130.Suppl_1.3135.3135

Published: 2017

Journal Articles

Small Molecule SHIP Agonist AQX-MN100 Inhibits Multiple Myeloma (MM) Cell Growth In NOD/SCID Mice and Reduces Immune Suppressive Myeloid Derived Suppressor Cells (MDSC) and Regulatory T Cells (Tregs) In Mouse Model

Alice Mui, PhD, Mike Kennah, Christopher Ong, PhD, Raymond Anderson, Heather Sutherland, MD, PhD, FRCPC

Blood (2010) 116 (21): 792.

https://doi.org/10.1182/blood.V116.21.792.792

Published: 2010

Journal Articles

The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.

Christopher P. Venner, MD, Heather Sutherland, MD, PhD, FRCPC, John Shepherd, MD, FRCPC, Yasser Abou Mourad, MD, Michael J. Barnett, BMBS, Donna L. Forrest, MD, Donna E. Hogge, MD, PhD, Stephen H. Nantel, MD, FRCPC, Sujaatha Narayanan, MD, Thomas J. Nevill, MD, FRCPC, Janet Nitta, Maryse Power, MD, FRCPath, Cynthia Toze, MD, FRCPC, Clayton Smith, Kevin Song, MD

Blood (2010) 116 (21): 4580.

https://doi.org/10.1182/blood.V116.21.4580.4580

Published: 2010

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.

Cynthia Toze, MD, FRCPC, Chinmay B. Dalal, MD, Tanya L. Gillan, PhD, FCCMG, Thomas J. Nevill, MD, FRCPC, Michael J. Barnett, BMBS, Stephen H. Nantel, MD, FRCPC, Donna E. Hogge, MD, PhD, Donna L. Forrest, MD, Heather Sutherland, MD, PhD, FRCPC, Kevin Song, MD, Raewyn Broady, MBChB, FRACP, Maryse Power, MD, FRCPath, Sujaatha Narayanan, MD, Clayton A. Smith, MD, FRCPC, John Shepherd

Blood (2010) 116 (21): 3465.

https://doi.org/10.1182/blood.V116.21.3465.3465

Published: 2010

Journal Articles

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Robert Orlowski, MD, PhD, Heather Sutherland, MD, PhD, Joan Bladé, MD, Jesús San Miguel, MD, Roman Hájek, MD, PhD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Suneel Mundle, PhD, Donghan Luo, PhD, Sen Hong Zhuang, MD, PhD, Jean-Luc Harousseau, MD

Blood (2007) 110 (11): 2735.

https://doi.org/10.1182/blood.V110.11.2735.2735

Published: 2007

Journal Articles

Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.

David A. Irvine, Michael J. Barnett, Ryan Brinkman, Donna L. Forrest, Donna E. Hogge, Julye Lavoie, Linda Lei, Stephen H. Nantel, Thomas J. Nevill, Janet Nitta, John Shepherd, Kevin Song, Cynthia Toze, Heather Sutherland

Blood (2006) 108 (11): 3098.

https://doi.org/10.1182/blood.V108.11.3098.3098

Published: 2006

NARROW

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)

Small Molecule SHIP Agonist AQX-MN100 Inhibits Multiple Myeloma (MM) Cell Growth In NOD/SCID Mice and Reduces Immune Suppressive Myeloid Derived Suppressor Cells (MDSC) and Regulatory T Cells (Tregs) In Mouse Model

The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.

Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.

Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only